Table 2.
Pathological characteristics of patients
| Parameter | Age ≤55 (n = 315) | Age 56–65 (n = 1,098) | Age >65 (n = 960) | p | Total (n = 2,373) |
|---|---|---|---|---|---|
| Pathological stage pT2 pT3a pT3b |
216 (68.6) 83 (26.3) 16 (5.1) |
717 (65.3) 293 (26.7) 88 (8.0) |
604 (62.9) 277 (28.9) 79 (8.2) |
0.23 |
1,537 (64.8) 653 (27.5) 183 (7.7) |
| Pathological GS 3+3 3+4 4+3 8 9–10 |
83 (26.3) 172 (54.6) 35 (11.1) 13 (4.1) 12 (3.8*) |
286 (26.0) 602 (54.8) 124 (11.3) 36 (3.3) 50 (4.6) |
257 (26.8) 485 (50.5) 87 (9.1) 58 (6.0) 73 (7.6*) |
0.002 |
626 (26.4) 1,259 (53.1) 246 (10.4) 107 (4.5) 135 (5.7) |
| HRPCa | 105 (33.3*) | 415 (37.8) | 401 (41.8*) | 0.018 | 921 (38.8) |
| PLND | 82 (26.0*) | 321 (29.3#) | 375 (39.1*#) | 0.001 | 779 (32.8) |
| Positive LN | 13/82 (15.9) | 32/321 (10.0) | 37/375 (9.9) | 0.225 | 82/779 (10.6) |
| LN removed | 7 (4–12) | 7 (4–11) | 6 (4–9) | 6 (4–10) | |
| Positive LN removed | 2 (2–3) | 2 (1–2) | 1 (1–2) | 2 (1–2.5) |
Data presented as median (quartiles) or number (%), GS – Gleason Score
* #
p<0.05
HRPCa – high-risk prostate cancer, PLND – pelvic lymph node dissection, LN – lymph nodes